Analysts Set Pulmonx Co. (NASDAQ:LUNG) PT at $14.83

Shares of Pulmonx Co. (NASDAQ:LUNG) have been given a consensus rating of “Moderate Buy” by the six brokerages that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $14.67.

LUNG has been the topic of several analyst reports. Wells Fargo & Company reduced their target price on Pulmonx from $14.00 to $10.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. Stifel Nicolaus cut their price target on shares of Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Finally, Canaccord Genuity Group lifted their price objective on Pulmonx from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st.

Pulmonx Stock Up 13.6 %

Shares of LUNG stock opened at $7.12 on Tuesday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.92 and a current ratio of 8.97. The business has a fifty day simple moving average of $7.23 and a 200 day simple moving average of $7.24. Pulmonx has a twelve month low of $5.46 and a twelve month high of $14.84.

Pulmonx (NASDAQ:LUNG) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The business had revenue of $20.39 million during the quarter, compared to analyst estimates of $20.39 million. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 51.92%. During the same quarter last year, the business earned ($0.39) EPS. On average, research analysts predict that Pulmonx will post -1.53 EPS for the current fiscal year.

Insider Activity

In other news, CEO Steven S. Williamson purchased 14,245 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The shares were acquired at an average cost of $6.84 per share, with a total value of $97,435.80. Following the purchase, the chief executive officer now owns 219,531 shares in the company, valued at $1,501,592.04. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, CEO Steven S. Williamson bought 14,245 shares of the business’s stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average cost of $6.84 per share, for a total transaction of $97,435.80. Following the acquisition, the chief executive officer now directly owns 219,531 shares in the company, valued at approximately $1,501,592.04. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Geoffrey Beran Rose sold 4,586 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $6.70, for a total transaction of $30,726.20. Following the sale, the insider now directly owns 295,433 shares of the company’s stock, valued at approximately $1,979,401.10. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 50,351 shares of company stock worth $361,494. Company insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in Pulmonx by 609.7% in the first quarter. Allspring Global Investments Holdings LLC now owns 8,516 shares of the company’s stock worth $79,000 after purchasing an additional 7,316 shares during the last quarter. Sei Investments Co. grew its stake in Pulmonx by 2.5% during the first quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock valued at $673,000 after acquiring an additional 1,800 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Pulmonx by 6.4% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 989,423 shares of the company’s stock valued at $9,172,000 after acquiring an additional 59,835 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Pulmonx by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 2,077,859 shares of the company’s stock worth $19,262,000 after acquiring an additional 11,417 shares during the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in Pulmonx during the first quarter valued at about $102,000. 91.04% of the stock is owned by institutional investors.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.